Replimune Group (NASDAQ:REPL) Stock Rating Upgraded by JPMorgan Chase & Co.
Replimune Group (NASDAQ:REPL) was upgraded by research analysts at JPMorgan Chase & Co. from a “neutral” rating to an “overweight” rating in a research note issued on Friday, MarketBeat Ratings reports. The brokerage currently has a $26.00 price objective on the stock, down from their previous price objective of $27.00. JPMorgan Chase & Co.‘s price target points to a potential upside of 98.17% from the company’s previous close.
Several other analysts also recently commented on the stock. Wedbush cut their price objective on shares of Eiger Biopharmaceuticals from $43.00 to $35.00 and set an “outperform” rating on the stock in a research report on Wednesday, April 24th. HC Wainwright set a $73.00 price objective on shares of Uniqure and gave the company a “buy” rating in a research report on Monday, July 8th. Finally, Zacks Investment Research raised shares of HB Fuller from a “sell” rating to a “hold” rating in a research report on Wednesday, July 3rd. Six analysts have rated the stock with a buy rating, The company presently has a consensus rating of “Buy” and an average price target of $24.67.
Shares of REPL stock opened at $13.12 on Friday. Replimune Group has a one year low of $8.88 and a one year high of $23.55. The company’s 50-day moving average price is $13.53. The company has a current ratio of 14.26, a quick ratio of 14.26 and a debt-to-equity ratio of 0.05.
About Replimune Group
Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company uses its proprietary Immulytic platform to design and develop product candidates that are intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1 that is in Phase I/II clinical trials for a range of solid tumors.
Further Reading: Purposes and Functions of the Federal Reserve
Receive News & Ratings for Replimune Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Replimune Group and related companies with MarketBeat.com's FREE daily email newsletter.